Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2007

01-06-2007 | Hepatic and Pancreatic Tumors

Optimization of Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin Plus Irinotecan at 43°C After Compete Cytoreductive Surgery: Mortality and Morbidity in 106 Consecutive Patients

Authors: Dominique Elias, Diane Goere, François Blot, Valérie Billard, Marc Pocard, Niaz Kohneh-Shahri, Bruno Raynard

Published in: Annals of Surgical Oncology | Issue 6/2007

Login to get access

Abstract

Background

Peritoneal carcinomatosis (PC), which has hitherto been regarded as a lethal entity, can now be cured with surgery (treating macroscopic tumor seeding) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) (treating residual microscopic disease). The purpose of this study was to analyze the morbidity and mortality of a particular approach associating optimal (R0–R1) cytoreduction, optimal HIPEC combining oxaliplatin and irinotecan, and an optimal homogeneous intraperitoneal temperature of 43°C.

Methods

A total of 106 consecutive patients were included in this prospective phase 2 study. After complete resection of the PC, HIPEC was performed by the Coliseum technique with oxaliplatin (360 mg/m2) combined with irinotecan (360 mg/m2) in 2 L/m2 of 5% dextrose, over 30 minutes at a real intraperitoneal temperature of 43°C. During the hour preceding HIPEC, patients received 5-fluorouracil (400 mg/m2) and leucovorin (20 mg/m2) intravenously, resulting in tritherapy.

Results

Postoperative mortality and morbidity rates were 4% and 66%, respectively. The most frequent complications were digestive fistula (24%), lung infection (16%), and severe hematological toxicity (11%). Statistical correlation was evidenced between morbidity and the carcinomatosis score (P = .0008), the number of resected organs (P = .0001), the duration of surgery (P = .0001), and blood loss (P = .0001).

Conclusions

This new approach, optimized in three respects (complete cytoreduction, combination oxaliplatin with irinotecan, and high temperature) has resulted in a relatively high but acceptable incidence of adverse events considering the expected advantage for survival.
Literature
1.
Sugarbaker PH, Cuniffe W, Belliveau JF, de Bruin E, Graves T. Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1988;1:66–79
2.
Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996;20:585–92PubMedCrossRef
3.
Fujimoto S, Shresta RD, Kokubun M, et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far advanced gastric cancer. Ann Surg 1990;212:592–6PubMedCrossRef
4.
Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71–6PubMedCrossRef
5.
Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cisplatinum in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;48:3380–4
6.
Zoetmulder FA. Cancer cell seeding during abdominal surgery: experimental studies. In: Sugarbaker PH, ed. Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer Acadademic Publishers, 1996:155–62
7.
Jacquet P, Elias D, Sugarbaker P. L’implantation tumorale dans les sites de cicatrisation après chirurgie des cancers digestifs. J Chir (Paris) 1996;133:175–82
8.
Elias D, Ouellet JF. Intraperitoneal chemohyperthermia. Rationale, technique, indications and results. Surg Oncol Clin N Am 2001;10:915–33PubMed
9.
Ceelen WP, Hesse U, de Hemptinne B, Pattyn P. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg 2000;87:1006–15PubMedCrossRef
10.
Rietbroeck RC, van de Vaart PJ, Haveman J, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997;123:6–12CrossRef
11.
Elias D, Raynard B, Farkhondeh F, et al. Peritoneal carcinomatosis of colorectal origin: long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroenterol Clin Biol 2006;30:1200–4PubMed
12.
Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first line chemotherapy in metastatic colorectal cancer. J Clin Oncol 1998;16:2739–44PubMed
13.
Giachetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomoduled fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–47
14.
De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47PubMed
15.
Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14:254–61PubMedCrossRef
16.
Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437–44PubMedCrossRef
17.
Elias D, Antoun A, Goharin A, et al. Research on the best chemohyperthermia technique for treatment of peritoneal carcinomatosis after complete resection. Int J Surg Invest 2000;1:431–9
18.
Elias D, Bonnay M, Puizillou JM, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002;13:267–72PubMedCrossRef
19.
Le Page S, Kwiatkowski F, Paulin C, et al. In vitro thermochemotherapy of colon cancer cell lines with irinotecan alone and combined with mitomycin C. Hepatogastroenterology 2006;53:693–7PubMed
20.
Rougier P, van Custem E, Bajetta E, et al. Randomized trial of irinotecan versus flourouracyl by continuous infusion after fluouracyl failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407–12PubMedCrossRef
21.
Hribaschek A, Pross M, Kuhn R, et al. Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 or oxaliplatin. Anti-Cancer Drugs 2002;13:605–14PubMedCrossRef
22.
Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 2004;15:1558–65PubMedCrossRef
23.
Elias D, Dube P, Bonvalot S, et al. A treatment of liver metastases with moderate peritoneal carcinomatosis by hepatectomy and cytoreductive surgery followed by immediate postoperative intraperitoneal chemotherapy. Feasibility and preliminary results. Hepatogastroenterology 1999;46:360–3PubMed
24.
Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of the complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004;11:518–21PubMedCrossRef
25.
26.
Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetics changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 2006;57:703–8PubMedCrossRef
27.
Martin RC, Brennan MF, Jacques DP. Quality of complication reporting in the surgical literature. Ann Surg 2002;235:803–13PubMedCrossRef
28.
Verwaal V, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43PubMedCrossRef
29.
Glehen O, Kwiatowsky F, Sugarbaker P, et al. Cytoreductive surgery combined with intraperitoneal chemotherapy for management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284–92PubMedCrossRef
30.
Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of the complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004;11:518–21PubMedCrossRef
31.
Shimizu T, Maeta M, Koga S. Influence of local hyperthermia on the healing of small intestinal anastomosis in the rat. Br J Surg 1991;78:57–9PubMedCrossRef
32.
Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790–6PubMedCrossRef
33.
Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003;10:863–9PubMedCrossRef
34.
Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei. A report of 103 procedures. Eur J Surg Oncol 2006;32:186–90PubMedCrossRef
35.
Elias D, Raynard B, Boige V, et al. Impact of the extent and duration of cytoreductive surgery on postoperative haematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 2005;90:220–5PubMedCrossRef
Metadata
Title
Optimization of Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin Plus Irinotecan at 43°C After Compete Cytoreductive Surgery: Mortality and Morbidity in 106 Consecutive Patients
Authors
Dominique Elias
Diane Goere
François Blot
Valérie Billard
Marc Pocard
Niaz Kohneh-Shahri
Bruno Raynard
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9348-1

Other articles of this Issue 6/2007

Annals of Surgical Oncology 6/2007 Go to the issue

Multimedia Article

Laparoscopic Medial-to-lateral Approach for the Curative Resection of Right-Sided Colon Cancer

OriginalPaper

Teaching Palliative Care and End-of-Life Issues: A Core Curriculum for Surgical Residents

OriginalPaper

Association of the Presence of Bone Marrow Micrometastases with the Sentinel Lymph Node Status in 410 Early Stage Breast Cancer Patients: Results of the Swiss Multicenter Study

Gynecologic Oncology

Determination of the Necessary Total Protein Substitution Requirements in Patients with Advanced Stage Ovarian Cancer and Ascites, Undergoing Debulking Surgery. Correlation with Plasma Proteins

Hepatic and Pancreatic Tumors

High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies

Educational Review

Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy